Ophthalmology Times

04/12/2026

What should primary care docs know about ? For Francis Mah, MD, the key thing is that they know it’s treatable, and that patients have options! He shared his insight at ASCRS on the topic.

04/12/2026

Yesterday, Nicole Bajic and a panel of others discussed the newly available TECNIS lenses from Johnson & Johnson | Vision, and why physicians in the states are so excited to see them enter practice. Her main takeaway? They’re helping to relieve anxieties for physicians and patients alike.

04/12/2026

Researchers at the University of Pittsburgh School of Medicine (UPMC) have developed an experimental “living eye drop” that uses a naturally occurring ocular bacterium to support corneal wound healing, according to a proof-of-concept study published March 5, 2026, in Cell Reports.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

04/12/2026

What has Francis Mah, MD, been hearing around the conference center at ASCRS? The things that stand out are the advances, issues, and of course, disease.

What themes have stood out to you?

04/11/2026

Jason Bacharach, MD, of North Bay Eye Associates, walked us through his thinking when deciding between latanoprostene bunod (Vyzulta; Bausch + Lomb) and prostaglandin as a first-line treatment for patients with or .

04/11/2026

We caught up with Nicole Bajic on the floor at ASCRS to chat about post surgery patients who want to go glasses-free, and why emotional intelligence is key to those conversations.

04/11/2026

At ASCRS, we asked Mark Gallardo, MD, of El Paso Eye Surgeons, how he’d decide on a procedure for a patient with uncontrolled disease on 2 medications.

The answer? Trust what feels right in your hands.

04/11/2026

Amgen announced positive topline results from the phase 3 study of subcutaneous injection of TEPEZZA (teprotumumab-trbw) for moderate-to-severe thyroid eye disease (TED).

TEPEZZA, the first and only approved treatment for TED, when injected subcutaneously, was found to have efficacy that is comparable to intravenous treatment, including a 77% proptosis response and a reduction in eye bulging that exceeded 3 mm over 24 weeks, according to the press release.

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

04/10/2026

Here at the ASCRS annual meeting, we asked Nandini Venkateswaran, MD (Nandini Venkat) what she’d choose between and for a healthy 21-year-old patient with a -4.0D prescription.

Here’s what she had to say:

04/10/2026

Kevin Miller, MD, of UCLA Health, discussed the potential of robotics being used in surgery in the next 5 years and what a realistic timeline might look like there at the ASCRS annual meeting.

04/10/2026

Kenneth Beckman, MD, offered his perspective on a theoretical patient in their early 20s presenting with progressive keratoconus, and how he’d make the choice between epi-on and epi-off at the ASCRS annual meeting.

04/10/2026

Merck has initiated MALBEC, its phase 2b/3 clinical trial evaluating MK-8748 (also known as Tiespectus, EYE201) for the treatment of neovascular (wet) age-related macular degeneration (AMD).

MK-8748 is defined by the company as a “novel investigational bispecific antibody with a dual mechanism that directly activates the Tie2 pathway and inhibits VEGF with the goal of stabilizing retinal and choroidal blood vessels and reducing fluid accumulation in the macula.”

MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).